Form 4: Leap Therapeutics Director Nissim Mashiach Acquires 25,000 Stock Options

Director Nissim Mashiach acquired 25,000 stock options in Leap Therapeutics, Inc. on October 2, 2024, according to a Form 4 filing.

Summary

• Nissim Mashiach, a director of Leap Therapeutics, Inc., acquired 25,000 stock options on October 2, 2024.
• The options have an exercise price of $2.45.
• The options were granted pursuant to Leap's 2022 Equity Incentive Plan, as amended.
• The options vest in four quarterly installments starting December 31, 2024, and ending September 30, 2025, contingent on continued service as a director, consultant, or service provider.
• The expiration date for the options is October 2, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director. While insider ownership can be a positive signal, this event itself doesn't strongly indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is contingent upon the reporting person's continued service as a director, consultant, or service provider of the company.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their potential alignment with shareholder interests.

Stakeholder Impact

• Shareholders may view the granting of stock options to a director as a sign of alignment between management and shareholder interests.

Key Dates